Core One Labs Inc (CLABF)
0.0924
+0.01
(+10.70%)
USD |
OTCM |
Sep 27, 14:18
Core One Labs Revenue (Quarterly): 0.0688M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.0688M |
| September 30, 2023 | 0.052M |
| December 31, 2022 | 0.1962M |
| September 30, 2022 | 0.0867M |
| June 30, 2022 | 0.1067M |
| March 31, 2022 | 0.1042M |
| December 31, 2021 | 0.3424M |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | |
| December 31, 2020 | |
| September 30, 2020 | |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | -3.317M |
| September 30, 2019 | 0.4583M |
| June 30, 2019 | 0.7908M |
| Date | Value |
|---|---|
| March 31, 2019 | 2.041M |
| December 31, 2018 | 2.393M |
| September 30, 2018 | 0.4594M |
| June 30, 2018 | 0.2446M |
| March 31, 2018 | |
| December 31, 2017 | -0.4939M |
| September 30, 2017 | |
| June 30, 2017 | 0.4771M |
| March 31, 2017 | 0.134M |
| December 31, 2016 | 0.0248M |
| September 30, 2016 | |
| June 30, 2016 | 0.0112M |
| March 31, 2016 | 0.0063M |
| December 31, 2015 | -0.0099M |
| September 30, 2015 | 0.0312M |
| June 30, 2015 | 0.025M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
-3.317M
Minimum
Dec 2019
0.4583M
Maximum
Sep 2019
-0.2113M
Average
0.1042M
Median
Mar 2022
Revenue (Quarterly) Benchmarks
| Acasti Pharma Inc | -- |
| Aurinia Pharmaceuticals Inc | 57.19M |
| Edesa Biotech Inc | -- |
| Lexaria Bioscience Corp | 0.084M |
| InMed Pharmaceuticals Inc | 1.173M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -0.6175M |
| Total Expenses (Quarterly) | 0.3829M |
| EPS Diluted (Quarterly) | -0.0147 |
| Enterprise Value | 4.003M |
| Profit Margin (Quarterly) | -897.5% |
| Earnings Yield | -81.21% |
| Normalized Earnings Yield | -59.47 |